6943-79-9

Usage

Uses

Used in Pharmaceutical Industry:
4-(2-methylphenyl)butanoic acid is utilized as a chiral auxiliary in the synthesis of various drugs, playing a crucial role in the production of pharmaceuticals due to its ability to influence the stereochemistry of the synthesized compounds.
Used in Medication Development:
4-(2-methylphenyl)butanoic acid is employed as an anti-inflammatory and analgesic agent, contributing to the development of new medications aimed at pain relief and inflammation management, thanks to its inherent properties that can be harnessed therapeutically.
Used in Flavoring Agent Development:
4-(2-methylphenyl)butanoic acid is studied for its potential use as a flavoring agent in the food industry, capitalizing on its fruity and sweet aroma to enhance the sensory attributes of food products.

InChI:InChI=1/C11H14O2/c1-9-5-2-3-6-10(9)7-4-8-11(12)13/h2-3,5-6H,4,7-8H2,1H3,(H,12,13)

Upstream product

• 21851-78-5 1-(3-bromopropyl)-2-methylbenzene 
• 6939-36-2 4-(2-methylphenyl)-4-oxobutanoic acid 
• 100118-01-2 (2-methyl-phenethyl)-malonic acid 
• 42946-77-0 5-ortho-tolylpentene 
• 120347-16-2 4-(4-chloro-o-tolyl)butyric acid 
• 14902-36-4 3-(2-methylphenyl)-1-propanol 
• 108-41-8 1-chloro-3-methylbenzene 
• 1587-04-8 1-methyl-2-(2-propenyl)-benzene 
• 2373-76-4 2-methylcinnamic acid 
• 22084-89-5 3-(2-methylphenyl)propanoic acid 
• 951247-74-8 C₁₁H₁₆O₃S 
• 41010-06-4 4-(o-tolyl)butanenitrile 
• 91193-36-1 4-(4-chloro-2-methylphenyl)-4-oxobutanoic acid 
• 269084-19-7 diethyl 2-[2-(2-methylphenyl)ethyl]propanedioate 

Downstream Products

• 6939-35-1 5-methyl-1-tetralone 
• 23203-37-4 5-methyl-3,4-dihydro-2H-naphthalen-1-one semicarbazone 
• 23203-36-3 5-methyl-3,4-dihydro-2H-naphthalen-1-one-(2,4-dinitro-phenylhydrazone) 
• 65462-67-1 methyl 4-(o-tolyl)butanoate 
• 192987-41-0 4-[1-(1-hydroxy-5-methyl-1,2,3,4-tetrahydronaphthyl)]-N-(triphenylmethyl)imidazole 
• 45892-60-2 1-(but-3-en-1-yl)-2-methylbenzene 
• 105986-51-4 ethyl 4-(o-tolyl)butanoate 
• 859809-70-4 4-o-tolyl-butyryl chloride 
• 81676-04-2 5-(2-methylphenyl)dihydrofuran-2-one 

Relevant academic research and scientific papers

Carbonylative Transformation of Allylarenes with CO Surrogates: Tunable Synthesis of 4-Arylbutanoic Acids, 2-Arylbutanoic Acids, and 4-Arylbutanals

In this Communication, procedures for the selective synthesis of 4-arylbutanoic acids, 2-arylbutanoic acids, and 4-arylbutanals from the same allylbenzenes have been developed. With formic acid or TFBen as the CO surrogate, reactions proceed selectively and effectively under carbon monoxide gas-free conditions.

THERAPEUTIC FLUOROETHYLCYANO GUANIDINES

Disclosed herein is compound having a formula as described herein. Therapeutic methods, compositions, and medicaments related thereto are also disclosed.

SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS

Therapeutic compounds, and methods, compositions, and medicaments related thereto are disclosed herein.

Hexa-cyclic compound

A novel hexa-cyclic compound, a derivative of camptothecin, of the general formula: STR1 The compound is prepared from an aminoketone compound and a pyranoindolizine compound by the condensation-ring closing reaction. It is abundantly water-soluble, and has an excellent antitumour activity and a high degree of safety, and can be applied as an antitumour medicine for curing tumors of various kinds.

Medetomidine analogs as α2-adrenergic ligands. 3. Synthesis and biological evaluation of a new series of medetomidine analogs and their potential binding interactions with α2-adrenoceptors involving a 'methyl pocket'

The synthesis and the biological evaluation of a new series of medetomidine analogs are reported. The substitution pattern at the phenyl ring of the tetralin analogs had a distinct influence on the α2- adrenoceptor binding affinity. 4-Methylindan analog 6 was the most potent α2-adrenoceptor binding ligand among these 4-substituted imidazoles, and its α2-adrenoceptor selectivity was greater than the 5-methyl tetralin analog 4c. Ligand-pharmacophore and receptor modeling were combined to rationalize α2-adrenoceptor binding data of the imidazole analogs in terms of ligand-receptor interactions. The structure-activity relationships that were apparent from this and previous studies were qualitatively rationalized by the binding site models of the α2-adrenoceptor. The benzylic methyl group of medetomidine or the naphthyl analog 2a was superimposable with the α-methyl group of (-)-α-methylnorepinephrine and fit into the proposed 'methyl pocket' of the α2-adrenoceptor defined by the residues Leu110, Leu169, Phe391, and Thr395.